Director: *Mrs D Pritchard*
Operations Manager: *Miss A De'Ath*

Tel: *+44 (0) 1443 622185*
Email: *uknegashandi@wales.nhs.uk*
Web: *www.uknegashandi.org.uk*

UK NEQAS for H&I
Welsh Blood Service
Ely Valley Road
Talbot Green
Pontyclun
CF72 9WB

SCHEME 5B - INTERPRETIVE: HFE GENOTYPE AND HEREDITARY HAEMOCHROMATOSIS

Please note: The patient information given is fictitious and for UK NEQAS for H&I external quality assessment purposes only

- Please make a report using your usual reporting format.
- The report should contain sufficient information to be of use to clinical staff involved in the patient's care and treatment.
- Reports should be uploaded to the Participant's Portal by **25th June 2024**.
- Reports can be added to the Participant's Portal by following the instructions in the user guide found at: https://uknegashandi.org.uk/scheme-5b-results-submission-help/

CLINICAL SCENARIO 1/2024

GP Surgery: Dr Davenport, Davenport GP Practice, 219 Hill Road Leicester LE65, UK
Patient Name: Jane Fenton
Patient Address: 115 The Valley, Leicester LE64
DOB: 17/02/1974

Genotype: Homozygous for *p.Cys282Tyr* variant
Ferritin: 295 µg/L
TS%: 62% (non-fasting) & 52% (repeat fasting sample)
Other: Normal Liver profile & normal serum glucose.
Reason for request: Family screening for HFE; Brother (38yrs) tested homozygous for *p.Cys282Tyr* upon investigation of abnormally raised biochemical indices (ALT 60 IU/L, ferritin 500µg/l & repeat fasting TS of 80%) with arthralgia
Clinical information: Post-menopausal for 2 years
Other: One daughter **(**20yrs) & one son (28yrs**)**
Date of receipt of sample: 02/04/2024

You are required to write a genetic report to Jane's GP clearly stating diagnosis, risk & all follow up actions required. In the report you are required to state all HFE genetic results according to HGVS nomenclature. (Please refer to best practice guidelines. Porto, G., Brissot, P., Swinkels, D. *et al.* EMQN best practice guidelines for the molecular genetic diagnosis of hereditary hemochromatosis (HH). *Eur J Hum Genet* **24**, 479–495 (2016). https://doi.org/10.1038/ejhg.2015.128)

You are also required to comment on the clinical penetrance of HFE with regard to the patients age & biological sex as the has GP previously phoned the lab with a general query in relation age of onset of symptoms in HFE.

The report should contain sufficient information for the GP to determine what further action is required.

Director: *Mrs D Pritchard*
Operations Manager: *Miss A De'Ath*

Tel: *+44 (0) 1443 622185*
Email: *uknegashandi@wales.nhs.uk*
Web: *www.uknegashandi.org.uk*

UK NEQAS for H&I
Welsh Blood Service
Ely Valley Road
Talbot Green
Pontyclun
CF72 9WB

CLINICAL SCENARIO 2/2024

GP Surgery: Dr Jones, Dinas Surgery, Scarlet Road, LL00 5SQ
Name: Arwel Thomas
Patient Address: 18 Violet Terrace, LL00 5SQ
DOB: 27/05/1990
NHS: 109 876 5431
Genotype: Homozygous for *p.His63Asp* variant
Ferritin: 150 µg/L
TS%: 44% (fasting sample)
Clinical details. Fatigue**.** Father had a haemochromatosis variant and died mid 60's with a hepatocarcinoma. Worried about his 18 year old son. Mother's genotype unknown.
Date of receipt of sample: 15th March 2024

You are required to write a report to Arwel's GP clearly stating diagnosis, risk & all follow up actions required for Arwel and his son. In the report you are required to state all HFE genetic results according to HGVS nomenclature. (Please refer to best practice guidelines. Porto, G., Brissot, P., Swinkels, D. *et al.* EMQN best practice guidelines for the molecular genetic diagnosis of hereditary hemochromatosis (HH). *Eur J Hum Genet* **24**, 479–495 (2016). https://doi.org/10.1038/ejhg.2015.128).

The report should contain sufficient information for the GP to determine what further action is required.